Andere talen Marvel Biosciences Corp.

Aandelen

MRVL

CA57384M1077

Beurs gesloten - Toronto S.E. Andere beurzen 21:22:39 29-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,15 ^CAD	+3,45%		+11,11%	+87,50%

26/03	Marvel Biosciences Corp. Rapporteert resultaten voor het tweede kwartaal en de zes maanden eindigend op 31 januari 2024	CI
25/03	Marvel Biosciences kondigt positieve tussentijdse resultaten aan voor MB-204	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	26/03
Marvel Biosciences Announces Positive Interim Results For MB-204	25/03
Marvel Biosciences Corp. and Marvel Biotechnology Inc. Announces Positive Interim Results on Tau Phosphorylation with MB-204	25/03
Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204	25/03
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB204	12/03
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204	12/03
Marvel Biosciences Announces Testing MB-204 on Autism by French University	20/02
Marvel Biosciences Corp. and Marvel Biotechnology Inc. Announces Testing MB-204 on Autism by French University	20/02
Marvel Biosciences Announces Testing MB-204 on Autism by French University	20/02
Marvel Biosciences Announces Closing of Non-Brokered Private Placement	19/01
Marvel Biosciences Corp. announced that it has received CAD 0.5 million in funding	19/01
Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel	08/01
Marvel Biosciences Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023	18/12
Marvel Biosciences Corp. Reports Earnings Results for the Full Year Ended July 31, 2023	28/11
Marvel Biosciences Invited to Test MB-204 on Autism by French University	16/11
Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials	22-08-23
Marvel Biosciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23-06-23
Marvel Successfully Completes the Dog and Rat GLP Toxicology Studies Required to enter Human Trials	21-04-23
Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	30-03-23
Marvel Biosciences Corp. and its Wholly Owned Subsidiary, Marvel Biotechnology Inc. Initiate 4-Week Good Laboratory Practice FDA Investigational New Drug Enabling Dose-Ranging Rat Studies for its Lead Drug Candidate MB-204	09-03-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Marvel Biosciences Corp.

Aandelen

MRVL

CA57384M1077

Andere talen

Filters